1. Petri, M. A. et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind randomized, placebo-controlled trial. Arthritis Rheum. 46, 1820–1829 (2002).
2. Petri, M. A. et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 50, 2858–2868 (2004).
3. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide as lupus nephritis induction treatment. J. Am. Soc. Nephrol. (in press).
4. Wallace, D. J. et al. Belimumab (Lymphostat-B) shows bioactivity and reduces SLE disease activity [Abstract]. Presented at the Annual Congress of the European League Against Rheumatism: Amsterdam, The Netherlands (22 June, 2006).
5. Wallace, D. J. et al. Belimumab reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks [Abstract]. Presented at the 70th Annual Scientific Meeting of the American College of Rheumatology: Washington, DC (14 November, 2006).